Lung Cancer, Small Cell
Conditions
Brief summary
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a real world approach of the diagnosis and treatment of patients with SCLC. Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.
Interventions
DRUGHYCAMTIN
Observing patients on HYCAMTIN and other drugs for SCLC.
Sponsors
GlaxoSmithKline
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or Female \>/= 18 years * Diagnosis of small cell lung cancer * Patient newly diagnosed with SCLC * Has given written informed consent (if applicable)
Exclusion criteria
* Concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix. * Patient presenting with recurrence of SCLC. * Patients who has received any chemotherapy for the SCLC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Registry with disease, treatment and outcome data collected. | 6-9mth recruitment period, 18mth study duration. |
Secondary
| Measure | Time frame |
|---|---|
| survival rates | 18 month period |
Countries
Austria, Czechia, Estonia, France, Germany, Greece, Hungary, Italy, Lithuania, Netherlands, Poland, Slovenia, South Korea, Spain
Outcome results
None listed